Emergent Biosolutions Canada Inc.
Winnipeg, MB
- UEI
- XM23STFMVML6
- CAGE
- L0EM2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Emergent Biosolutions Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Cangene Corporation 155 Innovation Drive, 155 Innovation Dr, Winnipeg, MB R3T 5Y3, Canada
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $118,251,472 |
| FY2025 | $114,301,000 |
| FY2024 | $122,975,784 |
| FY2023 | $131,546,433 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $118,251,472 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Reactive skin decon | Medical Supply Chain (DLA) | $108,377 | |
| Training aid, reacti | Medical Supply Chain (DLA) | $4,285 | |
| Reactive skin decon | Medical Supply Chain (DLA) | $123,191 | |
| "covid-19" development of human immune globulin (covid-HIG) manufactured from human plasma with antibodies to… | ACC Aberdeen Proving Ground | $34,568,578 | |
| Reactive skin decon | Medical Supply Chain (DLA) | $95,220 |
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Canadian Commercial Corporation | SPE2D626F01SV | $0 | |
| Canadian Commercial Corporation | SPE2D626F82A2 | $0 | |
| Canadian Commercial Corporation | SPE2D626F77Y0 | $0 | |
| Canadian Commercial Corporation | SPE2D626F68V5 | $0 | |
| Canadian Commercial Corporation | SPE2DP23D0001 | $0 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Emergent Product Development Gaithersburg Inc. | Gaithersburg, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Amgen Inc. | Thousand Oaks, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Emergent Countermeasures International LTD | — | 541713 Research and Development in Nanotechnology |
| Endo Usa, Inc. | Malvern, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Phlow Corp. | Richmond, VA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Emergent Biosolutions Canada Inc. is a for-profit organization that provides medical countermeasures to the U.S. government, including therapeutics and vaccines against chemical, biological, radiological and nuclear threats. Through federal contracts, the company supplies skin decontamination lotion, botulism antitoxin, and immune globulin to prevent and treat diseases.
Emergent has received over $770 million in federal contracts from agencies like the Defense Logistics Agency and the Department of Health and Human Services. As a prime contractor, it has provided skin decontamination lotion to the Defense Logistics Agency under purchase orders without set aside designations. It also holds multi-year definitive contracts valued at $133 million and $600 million with the HHS Office of the Assistant Secretary for Preparedness and Response to supply botulism antitoxin and vaccinia immune globulin. Additionally, Emergent received a $34 million Other Transaction Agreement from the Department of the Army to develop a COVID-19 therapy. As a subcontractor, Emergent has worked with the Canadian Commercial Corporation to manufacture reactive skin decontamination lotion.
Quick answers
Is Emergent Biosolutions Canada Inc. registered in SAM.gov?
Yes. Emergent Biosolutions Canada Inc.'s SAM.gov registration is active through September 24, 2027.
How much has Emergent Biosolutions Canada Inc. received in federal contracts?
Federal contracts obligated $114,301,000 to Emergent Biosolutions Canada Inc. in fiscal year 2025 and $487,074,689 in fiscal years 2023 through 2027.
How does Emergent Biosolutions Canada Inc. rank among federal contractors?
Emergent Biosolutions Canada Inc.'s parent company, Emergent Biosolutions Inc., ranked #4 in NAICS 3254, #6 in PSC 6505 and #8 in NAICS 325 in FY2025.
What is Emergent Biosolutions Canada Inc.'s most recent federal award?
Emergent Biosolutions Canada Inc.'s most recent federal contract award is Reactive skin decon (SPE2DP23P0208), from Medical Supply Chain (DLA), on January 11, 2023.
On GovTribe
See Emergent Biosolutions Canada Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors